VANCOUVER, British Columbia, Nov. 05, 2025 (GLOBE NEWSWIRE) — Western Forest Products Inc. (TSX: WEF) (“Western” or the “Company”) reported Adjusted EBITDA of negative $65.9 million in the third quarter of 2025, which included a non-cash export duty expense of $59.5 million related to the determination of final duty rates from the sixth Administrative Review (“AR”). In comparison, the Company reported Adjusted EBITDA of negative $10.7 million in the third quarter of 2024, which included a $1.0 million export duty recovery related to the determination of final duty rates from the fifth AR, and Adjusted EBITDA of $0.5 million in the second quarter of 2025. Net loss was $61.3 million in the third quarter of 2025, as compared to a net loss of $19.6 million in the third quarter of 2024, and net loss of $17.4 million in the second quarter...

BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September 30, 2025 and provided a corporate update. “We are continuing our strategic alternatives process with the goal of maximizing value for stockholders,” said Stephen Brady, president and chief executive officer of Tempest. “In addition, we look forward to the start of the TPST-1495 Phase 2 in collaboration with the NCI and the Cancer Prevention Clinical Trials Network and remain confident in the potential of amezalpat to transform the treatment of first-line HCC and bring meaningful benefit to patients and their families.” ——————  1 If approved...

Result for Q3 2025 The BANK of Greenland’s profit before tax amounts to DKK 132.5 million for the first nine months of 2025, compared to DKK 193.6 million for the same period of 2024. The profit before tax gives a return of 12.1% p.a. on opening equity after disbursement of dividend. The profit before value adjustments and write-downs amounted to DKK 133.4 million compared to DKK 186.2 million for the previous year. Net interest and fee income decreased by DKK 36.0 million to DKK 319.9 million compared to the same period in 2024.  At the end of September 2025, total costs including write-offs amounted to DKK 191.4 million, compared to DKK 173.8 million for the same period of 2024. At the end of September 2025, value adjustments show a capital gain of DKK 13.6 million, compared to a capital gain of DKK 22.6 million for the same period of...

ISTANBUL, , Nov. 05, 2025 (GLOBE NEWSWIRE) — D-MARKET Electronic Services & Trading (d/b/a “Hepsiburada”) (NASDAQ: HEPS), a leading Turkish e-commerce platform (referred to herein as “Hepsiburada” or the “Company”), today announces its unaudited financial results for the third quarter and the nine months ended September 30, 2025. Restatement of financial information: Pursuant to the International Accounting Standard 29, Financial Reporting in Hyperinflationary Economies (“IAS 29”), the financial statements of entities whose functional currency is that of a hyperinflationary economy must be adjusted for the effects of changes in a general price index. Turkish companies reporting under International Financial Reporting Standards (“IFRS”), including the Company, have been required to apply IAS 29 to their financial statements...

CHICAGO, Nov. 05, 2025 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management solutions provider, today reported its results for the third quarter 2025. GCM Grosvenor issued a detailed presentation of its results to the Public Shareholders section of GCM Grosvenor’s website at https://www.gcmgrosvenor.com/shareholder-events. The firm’s Board of Directors also approved a $0.12 per share dividend payable on December 15, 2025 to shareholders on record December 1, 2025. Conference Call A conference call to discuss GCM Grosvenor’s financial results will be held today, Wednesday, November 5, 2025, at 10:00 a.m. ET. The call will be accessible via public webcast from the Public Shareholders section of GCM Grosvenor’s website at https://www.gcmgrosvenor.com/shareholder-events, and a replay of the live broadcast...

MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025 ROCKVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its preliminary results for the third quarter ended September 30, 2025 and reiterated its 2025 revenue guidance. Preliminary Third Quarter Results and Recent HighlightsCore business revenue of $6.4 million in the third quarter of 2025. Strategic Platform License SPL Program-related revenue of $0.4 million in the third quarter of 2025. Total revenue...

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival (PFS) are expected in late Q1 2026. A new response in a third indication has been observed in the fifth and final dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody); no dose-limiting toxicities have been observed at any dose level and full topline data are now expected to be presented at a medical meeting in H1 2026. Based on previously reported responses in the CTX-8371 Phase 1 study, cohort expansions in patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), are expected to begin in Q4 2025. CTX-10726...

HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) — Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) today reported third-quarter 2025 results and provided the following highlights and recent developments: Third-Quarter Results and HighlightsReported net income attributable to PAA of $441 million and net cash provided by operating activities of $817 million. Delivered solid Adjusted EBITDA attributable to PAA of $669 million. Exited the quarter with 3.3x leverage ratio, toward the low-end of our target range of 3.25x – 3.75x. In September, Plains successfully raised $1.25 billion in aggregate senior unsecured notes with proceeds allocated toward redeeming senior notes maturing in October 2025 and to partially fund recently announced acquisitions.Recent DevelopmentsOn October 31st, Plains...

BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025. Business Updates  On October 23, 2025, the Company received $80 million in gross proceeds in a private placement, before deducting fees and other expenses. The financing includes an initial upfront funding of $80 million and up to an additional $80 million in gross proceeds if all Tranche A warrants are exercised, subject to the terms and conditions specified therein. Additional proceeds of $40 million may be received if all Tranche B warrants are exercised by cash payment upon the achievement of...

TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK; TSX:STCK.WT.A; TSX:STCK.WT.B) today announced its financial results for the quarter ended September 30, 2025. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Financial SummaryBook Value per Share (“BVpS”) was $14.26 as at September 30, 2025, compared to $14.34 at June 30, 2025. Total Book Value stood at $188.7 million. During the quarter, the Company successfully raised $35 million through a private placement, further strengthening its capital position as it actively pursues opportunities across late-stage, high-growth private companies.Portfolio Company Highlights SpaceXValuation increased from US$350B to US$400B during the quarter. Successfully completed its 11th Starship test...